Diffusely Abnormal White Matter, T2 Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis

被引:11
作者
Vertinsky, Alexandra T. [1 ]
Li, David K. B. [1 ,2 ,3 ]
Vavasour, Irene M. [1 ]
Miropolsky, Vladislav [1 ]
Zhao, Guojun [1 ,2 ]
Zhao, Yinshan [3 ]
Riddehough, Andrew [2 ]
Moore, G. R. Wayne [3 ,4 ,5 ]
Traboulsee, Anthony [2 ,3 ]
Laule, Cornelia [1 ,4 ,5 ,6 ]
机构
[1] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada
[2] Univ British Columbia, UBC MS MRI Res Grp, Vancouver, BC, Canada
[3] Univ British Columbia, Dept Med Neurol, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
[5] Univ British Columbia, ICORD, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada
关键词
Multiple sclerosis; magnetic resonance imaging; diffusely abnormal white matter; brain; longitudinal; prognosis; MAGNETIZATION-TRANSFER RATIO; FAST BLUE ARN; RELAXATION-TIME; INTERFERON BETA-1A; RESONANCE; MRI; MYELIN;
D O I
10.1111/jon.12574
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE Multiple sclerosis (MS) diffusely abnormal white matter (DAWM) is a mildly hyperintense magnetic resonance imaging abnormality distinct from typical lesions. Our goal was to investigate the prevalence and natural history of DAWM in a large cohort (n = 348) of relapsing-remitting MS (RRMS) patients. METHODS The presence of DAWM and relationship to changes in T-2 burden of disease (BOD), brain volume (brain fractional ratio, BFR), and disability (Expanded Disability Status Scale, EDSS) were investigated at baseline and year 7-8 (long-term follow-up, LTF). RESULTS DAWM was present in 25.3% (88 of 348) of patients at baseline. At LTF, DAWM was unchanged in 69.3% (61 of 88), decreased in 28.4% (25 of 88), and increased in 2.3% (2 of 88) of patients. Baseline BOD and change in BOD did not significantly differ between patients with and without DAWM. DAWM was associated with greater reduction in BFR at LTF (P = .038). DAWM and DAWM change did not predict EDSS or EDSS progression. CONCLUSIONS DAWM is present in a quarter of RRMS patients, and rarely increases or develops de novo. DAWM predicts brain atrophy but does not predict physical disability. Because of its posterior periventricular location, further investigation is warranted to evaluate its relationship to other measures of disability, including visual spatial processing and cognitive function.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 40 条
  • [1] Allen I V, 1981, Acta Neuropathol Suppl, V7, P176
  • [2] HISTOLOGICAL, HISTOCHEMICAL AND BIOCHEMICAL-STUDY OF THE MACROSCOPICALLY NORMAL WHITE MATTER IN MULTIPLE-SCLEROSIS
    ALLEN, IV
    MCKEOWN, SR
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1979, 41 (01) : 81 - 91
  • [3] THE LONGSTANDING MS LESION - A QUANTITATIVE MRI AND ELECTRON-MICROSCOPIC STUDY
    BARNES, D
    MUNRO, PMG
    YOUL, BD
    PRINEAS, JW
    MCDONALD, WI
    [J]. BRAIN, 1991, 114 : 1271 - 1280
  • [4] Diffuse signal abnormalities in the spinal cord in multiple sclerosis: Direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology
    Bergers, E
    Bot, JCJ
    van der Valk, P
    Castelijns, JA
    Lycklama, GJ
    Kamphorst, W
    Polman, CH
    Blezer, ELA
    Nicolay, K
    Ravid, R
    Barkhof, F
    [J]. ANNALS OF NEUROLOGY, 2002, 51 (05) : 652 - 656
  • [5] Multiple sclerosis: Magnetization transfer histogram analysis of segmented normal-appearing white matter
    Catalaa, I
    Grossman, RI
    Kolson, DL
    Udupa, JK
    Nyul, LG
    Wei, LG
    Zhang, X
    Polansky, M
    Mannon, LJ
    McGowan, JC
    [J]. RADIOLOGY, 2000, 216 (02) : 351 - 355
  • [6] Quantifying the Susceptibility Variation of Normal-Appearing White Matter in Multiple Sclerosis by Quantitative Susceptibility Mapping
    Chen, Weiwei
    Zhang, Yan
    Mu, Ketao
    Pan, Chu
    Gauthier, Susan A.
    Zhu, Wenzhen
    Wang, Yi
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 209 (04) : 889 - 894
  • [7] De Santis S, 2017, IEEE ENG MED BIO, P3024, DOI 10.1109/EMBC.2017.8037494
  • [8] Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis
    Dwyer, Michael G.
    Bergsland, Niels
    Ramasamy, Deepa P.
    Jakimovski, Dejan
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    [J]. JOURNAL OF NEUROIMAGING, 2018, 28 (05) : 490 - 495
  • [9] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [10] Ge YL, 2003, AM J NEURORADIOL, V24, P1935